Kinetics of self-induced aggregation of Brownian particles: non-Markovian and non-Gaussian features.

Phys Rev E Stat Nonlin Soft Matter Phys

Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700 032, India.

Published: November 2008

In this paper we have explored a model for self-induced aggregation of Brownian particles incorporating non-Markovian and non-Gaussian character of the associated random noise processes. The time evolution of each individual is guided by an overdamped Langevin equation of motion with a nonlocal drift arising out of the imbalance in the local distribution of the other individuals. Our simulation results show that colored noise enhances the tendency of cluster formation. Another observation is that the critical noise variance decreases at first with increase in noise correlation time followed by an increase after exhibiting a minimum. Furthermore, in the long time limit the cluster number in the aggregation process exhibits depletion with time following a power law with an exponent which increases remarkably with non-Markovian character of the noise processes.

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevE.78.051103DOI Listing

Publication Analysis

Top Keywords

self-induced aggregation
8
aggregation brownian
8
brownian particles
8
non-markovian non-gaussian
8
noise processes
8
noise
5
kinetics self-induced
4
particles non-markovian
4
non-gaussian features
4
features paper
4

Similar Publications

Objectives: Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, but no drugs can cure this disease. Chalcones possess good antioxidant activity, anti-neuroinflammatory activity, neuroprotective effects, inhibitory effects on Aβ aggregation, and Aβ disaggregation ability. Therefore, chalcones are ideal lead compounds, and the discovery of novel anti-AD agent-based chalcones is necessary.

View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a progressive neurodegenerative condition that leads to significant cognitive decline and motor dysfunction due to the loss of cholinergic neurons, with current medications only providing temporary relief of symptoms.
  • Novel compounds based on rivastigmine (such as 3q and 6e) were developed and shown to effectively inhibit key enzymes involved in AD, exhibit antioxidant properties, and prevent the aggregation of tau and Aβ proteins.
  • These compounds also reduced inflammation in brain cells and restored memory function in animal models, showing increased expression of neuroprotection markers, indicating their potential for treating AD more effectively than existing medications.
View Article and Find Full Text PDF

Alzheimer's disease (AD) is a neurodegenerative disease characterized by beta-amyloid (Aβ) deposition and increased acetylcholinesterase (AchE) enzyme activities. Indole 3 carbinol (I3C) and diindolylmethane (DIM) are reported to have neuroprotective activities against various neurological diseases, including ischemic stroke, Parkinson's disease, neonatal asphyxia, depression, stress, neuroinflammation, and excitotoxicity, except for AD. In the present study, we have investigated the anti-AD effects of I3C and DIM.

View Article and Find Full Text PDF

Alzheimer's disease is a complex neurological disorder linked with multiple pathological hallmarks. The interrelation of therapeutic targets assists in the enhancement of cognitive decline through interference with overall neuronal transmission. We have synthesized and screened various chromone derivatives as potential multitarget-directed ligands for the effective treatment of Alzheimer's disease.

View Article and Find Full Text PDF

Despite decades of research, Parkinson's disease is still an idiopathic pathology for which no cure has yet been found. This is partly explained by the multifactorial character of most neurodegenerative syndromes, whose generation involves multiple pathogenic factors. In Parkinson's disease, two of the most important ones are the aggregation of α-synuclein and oxidative stress.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!